Novel targeted therapies in head and neck cancer

Bibliography

• Moon C, Chae YK, Lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood) 2010;235(8):907-20
   PubMed Web of Science ®Google Scholar
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24(14):2137-50
   PubMed Web of Science ®Google Scholar
• Kutler DI, Auerbach AD, Satagopan J, High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003;129(1):106-12
   PubMed Web of Science ®Google Scholar
• Hopkins J, Cescon DW, Tse D, Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 2008;17(3):490-9
   PubMed Web of Science ®Google Scholar
• Cloos J, Spitz MR, Schantz SP. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88(8):530-5
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9-22
   PubMed Web of Science ®Google Scholar
• Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24(17):2644-52
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562-7
   PubMed Web of Science ®Google Scholar
• Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer–an update of recent developments. Head Neck Oncol 2:8
   PubMedGoogle Scholar
• Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009;60:207-19
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Kazi R, Bhide SA, Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents. Indian J Cancer 2010;47(3):248-59
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003;39(10):1348-54
   PubMed Web of Science ®Google Scholar
• Ang K, Berkey BA, Tu X, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350-6
   PubMed Web of Science ®Google Scholar
• Santini J, Formento JL, Francoual M, Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13(2):132-9
   PubMed Web of Science ®Google Scholar
• Dassonville O, Formento JL, Francoual M, Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11(10):1873-8
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78(6):1284-92
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579-84
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998;4(1):13-20
   PubMed Web of Science ®Google Scholar
• Klinghammer K, Knödler M, Schmittel A, Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2011;16(1):304-10
   Web of Science ®Google Scholar
• Cohen EE, Lingen MW, Martin LE, Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11(22):8105-8
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85
   PubMed Web of Science ®Google Scholar
• Sos ML, Koker M, Weir BA, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69(8):3256-61
   PubMed Web of Science ®Google Scholar
• Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7(Suppl 4):31-9
   PubMed Web of Science ®Google Scholar
• Gullick WJ. The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer 2001;8(2):75-82
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8
   PubMed Web of Science ®Google Scholar
• Lui VW JR. Grandis, EGFR-mediated cell cycle regulation. Anticancer Res 2002;22(1A):1-11
   PubMed Web of Science ®Google Scholar
• Zhang H, Alan Berezov A, Wang Q, ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117(8):2051-8
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787-99
   PubMed Web of Science ®Google Scholar
• Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009;20(10):851-5
   PubMed Web of Science ®Google Scholar
• Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49(2):427-33
   PubMed Web of Science ®Google Scholar
• Barnes CJ, Kumar R. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. Cancer Metastasis Rev 2003;22(4):301-7
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6(6):2166-74
   PubMed Web of Science ®Google Scholar
• Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001;1(4):719-32
   PubMed Web of Science ®Google Scholar
• Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002;1(7):507-14
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7(9):493-507
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Frampton JE. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 2010;70(15):1987-2010
   PubMed Web of Science ®Google Scholar
• Ang KK, Zhang Q, Rosenthal DI, A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). In American Society of Clinical Oncology annual meeting; Chicago, IL;2011
   Google Scholar
• Sok JC, Copelli FM, Thomas SM, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73
   PubMed Web of Science ®Google Scholar
• Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010;16(9):2489-95
   PubMed Web of Science ®Google Scholar
• Batra SK, Castelino-Prabhu S, Wikstrand CJ, Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6(10):1251-9
   PubMedGoogle Scholar
• Carteni G, Fiorentino R, Vecchione L, Panitumumab a novel drug in cancer treatment. Ann Oncol 2007;18(Suppl 6):vi16-21
   PubMedGoogle Scholar
• Wirth LJ, Allen AM, Posner MR, Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010;21(2):342-7
   PubMed Web of Science ®Google Scholar
• Bhide SA, Nutting CM. Advances in chemotherapy for head and neck cancer. Oral Oncol 2010;46(6): 436-8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Stohlmacher J, Davidenko I, Primary Efficacy and Safety Results of Spectrum, a Phase 3 Trial in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Receiving Chemotherapy with or without Panitumumab. In European Society for Medical Oncology Congress; Milan, Italy; 2010
   Google Scholar
• Bastholt L, Specht L, Jensen K. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007;85(1):24-8
   PubMed Web of Science ®Google Scholar
• Machiels JP, Henry S, Zanetta S, Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2009;28(1):21-8
   PubMed Web of Science ®Google Scholar
• Pytel D, Sliwinski T, Poplawski T, Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009;9(1):66-76
   PubMed Web of Science ®Google Scholar
• Cohen EE, Halpern AB, Kasza K, Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2009;45(10):e155-60
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980-7
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27(11):1864-71
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J. A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group (ECOG). In Annual meeting American Society of Clinical Oncology; Chicago, IL; 2009
   Google Scholar
• Siu LL, Soulieres D, Chen EX, Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25(16):2178-83
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies MS, Glisson BS. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. In Annual Meeting of American Society of Clinical Oncology; Chicago, IL; 2007
   Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr Opin Oncol 2010;22(6):586-91
   PubMed Web of Science ®Google Scholar
• Cohen EE, Davis DW, Karrison TG, Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-57
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Gooding WE, Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29(9):1140-5
   PubMed Web of Science ®Google Scholar
• Argiris A, Kotsakis AP, Kim S, Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC): Final results. In American Society of Clinical Oncology annual meeting; Chicago, IL; 2011
   Google Scholar
• Saura C, Baselga J, Herbst R, Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): an open-label exploratory study. J Clin Oncol 2009;27(15s):abstract 6023.
   Google Scholar
• Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008;61(2):179-88
   PubMed Web of Science ®Google Scholar
• Sano D, Kawakami M, Fujita K, Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007;17(2):289-95
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V, Heymach J, Frank SJ, Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. In American Society of Clinical Oncology annual meeting; Chicago, IL; 2011
   Google Scholar
• Williamson SK, Moon J, Huang CH, Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010;28(20):3330-5
   PubMed Web of Science ®Google Scholar
• Choong NW, Kozloff M, Taber D, Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010;28(5):677-83
   PubMed Web of Science ®Google Scholar
• Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602(2):114-30
   PubMed Web of Science ®Google Scholar
• Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19(49):5636-42
   PubMed Web of Science ®Google Scholar
• Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100(3):293-6
   PubMed Web of Science ®Google Scholar
• Bu R, Purushotham KR, Kerr M, Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors. Proc Soc Exp Biol Med 1996;211(3):257-64
   PubMed Web of Science ®Google Scholar
• Xi S, Zhang Q, Dyer KF, Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003;278(34):31574-83
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11(19 Pt 1):6924-32
   PubMed Web of Science ®Google Scholar
• Brooks HD, Glisson BS, Bekele BN, Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009;27(15s):abstract 6022.
   Google Scholar
• D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342(Pt 2):249-68
   PubMed Web of Science ®Google Scholar
• Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002;45(2):73-85
   PubMed Web of Science ®Google Scholar
• Smith S. The world according to PARP. Trends Biochem Sci. 2001;26(3):174-9
   PubMed Web of Science ®Google Scholar
• Miknyoczki SJ, Jones-Bolin S, Pritchard S, Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2(4):371-82
   PubMed Web of Science ®Google Scholar
• Delaney CA, Wang LZ, Kyle S, Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6(7):2860-7
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Curtin NJ, Newell DR, The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995;77(6):408-22
   PubMed Web of Science ®Google Scholar
• Bürkle A, Chen G, Küpper JH, Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis 1993;14(4):559-61
   PubMed Web of Science ®Google Scholar
• Khan K, Araki K, Wang D, Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010;32(3):381-91
   PubMed Web of Science ®Google Scholar
• Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127(7):411-17
   PubMed Web of Science ®Google Scholar
• Chan G, Boyle JO, Yang EK, Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59(5):991-4
   PubMed Web of Science ®Google Scholar
• Dannenberg AJ, Lippman SM, Mann JR, Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23(2):254-66
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Haddad RI, Lindeman NI, Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(28):6976-81
   PubMed Web of Science ®Google Scholar
• Choe MS, Chen Z, Klass CM, Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13(10):3015-23
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59(11):2615-22
   PubMed Web of Science ®Google Scholar
• Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995;2(8):503-8
   PubMed Web of Science ®Google Scholar
• Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989;243(4898):1576-83
   PubMed Web of Science ®Google Scholar
• King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274(5293):1652-9
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996;274(5293):1672-7
   PubMed Web of Science ®Google Scholar
• Kubicek GJ, Machtay M, Axelrod RA, Phase I trial of bortezomib (VELCADE), cisplatin and radiotherapy for advanced head and neck cancer. J Clin Oncol 2008;26(20 Suppl):abstract 6028.
   PubMedGoogle Scholar
• Chung CH, Aulino J, Muldowney NJ, Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010;21(4):864-70
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24(11):1770-83
   PubMed Web of Science ®Google Scholar
• Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv Cancer Res 1996;68:67-108
   PubMed Web of Science ®Google Scholar
• Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004;15(5):411-19
   PubMed Web of Science ®Google Scholar
• Tan AR, Headlee D, Messmann R, Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20(19):4074-82
   PubMed Web of Science ®Google Scholar
• Thomas JP, Tutsch KD, Cleary JF, Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50(6):465-72
   PubMed Web of Science ®Google Scholar
• Yeo W, Goh B, Le Tourneau C, A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol 2009;27(15s):abstract 6026.
   Google Scholar
• Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107(5):643-54
   PubMed Web of Science ®Google Scholar
• Maulik G, Kijima T, Ma PC, Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8(2):620-7
   PubMed Web of Science ®Google Scholar
• Maulik G, Madhiwala P, Brooks S, Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002;6(4):539-53
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002;109(7):857-62
   PubMed Web of Science ®Google Scholar
• Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2(4):289-300
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J. Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225(1):1-26
   PubMed Web of Science ®Google Scholar
• Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18(1):87-96
   PubMed Web of Science ®Google Scholar
• Gordon MS, Sweeney CS, Mendelson DS, Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16(2):699-710
   PubMed Web of Science ®Google Scholar
• Camacho LH, Bendell JC, John-Reid L, Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(Suppl):abstract e13008
   Google Scholar
• Seiwert T, Swann S, Kurz H, A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5-days-on/9-days-off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck in AACR-NCI-EORTC. International Conference: Molecular Targets and Cancer Therapeutics; Boston, MA; 2009
   Google Scholar
• Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9(3):288-96
   PubMed Web of Science ®Google Scholar
• Stallone G, Schena A, Infante B, Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317-23
   PubMed Web of Science ®Google Scholar
• Ekshyyan O, Rong Y, Rong X, Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009;8(8):2255-65
   PubMed Web of Science ®Google Scholar
• Liao YM, Kim C, Yen Y. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007;67(5):2160-8
   PubMed Web of Science ®Google Scholar
• Jimeno A, Kulesza P, Wheelhouse J, Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96(6):952-9
   PubMed Web of Science ®Google Scholar
• Oh SH, Kim WY, Kim JH, Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12(2):653-61
   PubMed Web of Science ®Google Scholar
• Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993;72(1):73-84
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84
   PubMed Web of Science ®Google Scholar
• Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007;6(11):2967-75
   PubMedGoogle Scholar
• Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26(1):81-7
   PubMed Web of Science ®Google Scholar
• Préville X, Salvemini F, Giraud S, Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp Cell Res 1999;247(1):61-78
   PubMed Web of Science ®Google Scholar
• Storm FK, Mahvi DM, Gilchrist KW. Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol 1996;3(6):570-3
   PubMed Web of Science ®Google Scholar
• Thanner F, Sütterlin MW, Kapp M, Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res 2005;25(3A):1649-53
   PubMed Web of Science ®Google Scholar
• Kassem HSH, Sangar V, Cowan R, A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 2002;101(5):454-60
   PubMed Web of Science ®Google Scholar
• Vargas-Roig LM, Gago FE, Tello O, Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79(5):468-75
   PubMed Web of Science ®Google Scholar
• Lo WY, Tsai MH, Tsai Y, Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 2007;376(1-2):101-7
   PubMed Web of Science ®Google Scholar
• Victora GD, Socorro-Silva A, Volsi EC, Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 2009;16(7):598-608
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang H, Lundgren K, BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 2010;126(5):1216-25
   PubMed Web of Science ®Google Scholar
• Kefford R, Millward M, Hersey P, Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma. J Clin Oncol 2007;25(18s):abstract 8558.
   Google Scholar
• Shillitoe EJ. Gene therapy: the end of the rainbow? Head Neck Oncol 2009;1:7
   PubMedGoogle Scholar
• Brieger J, Mann SA, Pongsapich W Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med. 2012 Mar;29(3):505-9
   PubMed Web of Science ®Google Scholar
• Demokan S, Chuang A, Suoğlu Y, Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer. Head Neck 2011 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar